» Articles » PMID: 22204712

Reduced Nuclear and Ectopic Cytoplasmic Expression of Lysyl Oxidase-like 2 is Associated with Lymph Node Metastasis and Poor Prognosis in Esophageal Squamous Cell Carcinoma

Overview
Journal Hum Pathol
Specialty Pathology
Date 2011 Dec 30
PMID 22204712
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Lysyl oxidase family members have various roles in cancer progression. The aim of this study was to investigate their expression and clinical significance in esophageal squamous cell carcinoma. We examined messenger RNA expression of lysyl oxidase family members including lysyl oxidase and lysyl oxidase-like proteins (lysyl oxidase L) in 10 esophageal squamous cell carcinoma cell lines and 83 pairs of tumor samples by quantitative real-time polymerase chain reaction. All except lysyl oxidase L3 were expressed at high levels in esophageal squamous cell carcinoma, but only lysyl oxidase L2 was associated with lymph node metastasis (P = .034). We examined lysyl oxidase L2 protein further by immunohistochemistry staining in 178 surgically resected esophageal squamous cell carcinoma tissue samples. The protein manifested decreased nuclear expression and increased cytoplasmic expression. Moreover, these 2 events both had significant correlation with the presence of lymph node metastasis (P = .001 and P < .001). Overall survival rates of the patients with esophageal squamous cell carcinoma with decreased nuclear expression or increased cytoplasmic expression of lysyl oxidase L2 were significantly lower than those of the patients with esophageal squamous cell carcinoma with the reverse expression pattern (P = .040 or P = .022). Multivariate analyses revealed that nuclear expression of lysyl oxidase L2 was an independent prognostic factor for esophageal squamous cell carcinoma. These results suggest that lysyl oxidase L2 exerts a critical effect on esophageal squamous cell carcinoma progression and can be a predictive marker of lymph node metastasis and outcome.

Citing Articles

The possibilities of LOXL4 as a prognostic marker for carcinomas.

Wang J, Chen C, Huang J, Xie Z, Chen X, Zheng Z Amino Acids. 2023; 55(11):1519-1529.

PMID: 37814029 DOI: 10.1007/s00726-023-03343-9.


A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer.

Xia Q, Du Z, Chen M, Zhou X, Bai W, Zheng X Mol Oncol. 2023; 17(11):2451-2471.

PMID: 37753805 PMC: 10620126. DOI: 10.1002/1878-0261.13529.


Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3.

Lu Y, Deng Y, Ko H, Peng H, Lee H, Yen-Ping Kuo M Cancer Sci. 2023; 114(10):3957-3971.

PMID: 37496288 PMC: 10551584. DOI: 10.1111/cas.15912.


Lysyl Oxidase Family Enzymes and Their Role in Tumor Progression.

Liburkin-Dan T, Toledano S, Neufeld G Int J Mol Sci. 2022; 23(11).

PMID: 35682926 PMC: 9181702. DOI: 10.3390/ijms23116249.


Prognostic Alternative Splicing Signatures in Esophageal Carcinoma.

Dlamini Z, Hull R, Mbatha S, Alaouna M, Qiao Y, Yu H Cancer Manag Res. 2021; 13:4509-4527.

PMID: 34113176 PMC: 8186946. DOI: 10.2147/CMAR.S305464.